Tolerability and Safety of HF1K16 Injection in Patients With Refractory Solid Tumors
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
HF1K16 is an investigational pegylated liposome formulation of All-Trans Retinoic Acid (ATRA)
for the induction of remission in patients with acute promyelocytic leukemia (APL) and for
the treatment of solid tumors through targeting myeloid derived suppressor cells (MDSCs).